Artery Therapeutics Announces Breakthrough Therapy for ApoE4 Alzheimer’s Disease Revealed in Peer-Review Publication

In the October publication of Journal of Alzheimer’s Disease it was shown that ABCA1 agonist CS6253 increases the lipidation of apoE4, resulting in full reversal of apoE4-driven Alzheimer’s disease, including brain hippocampus phenotype and cognition.

California, USA, and Tel Aviv, Israel (PRWEB) October 19, 2016 -- Artery Therapeutics, Inc., (Artery) today announced the publication of an article in the October issue of the Journal of Alzheimer’s Disease titled "ABCA1 agonist reverses the apoE4-driven cognitive and brain pathologies.” Daniel M. Michaelson is senior author.

The collaborative study conducted by Ramot at Tel Aviv University, Israel, and by Lawrence Berkeley National Laboratory (Berkeley Lab) and Artery in the U.S. shows reversal of the apoE4-driven Alzheimer’s disease by the ABCA1 agonist CS6253 in mice. ApoE4 is known to be the strongest genetic risk factor for late onset Alzheimer’s disease, and currently there is no treatment. The disruptive findings point to the potential of developing precision therapeutics for apoE4-based Alzheimer’s disease.

Professor Daniel M. Michaelson, PhD, Tel Aviv University, senior author of the publication and a known advocate of addressing the huge unmet medical need in apoE4 Alzheimer’s disease, said, “The observed ABCA1 target engagement and normalization of the apoE lipidation cause the reversal of apoE4-driven phenotype and cognition decline observed in the mice model, suggesting clinical potential for the ABCA1 agonist CS6253.”

John K. Bielicki, PhD, Berkeley Lab, noted. “These very exciting results open the door to potential new treatments for Alzheimer’s disease, and perhaps other brain disorders, using a targeted peptide approach.”

Artery CEO Jan O. Johansson, MD, PhD, stated that “CS6253 is a candidate drug in IND enabling progress with favorable drugability and safety index. It has the potential to address a specific segment of Alzheimer’s patients – those homozygous for apoE4.”

About Artery Therapeutics, Inc. Artery is a San Francisco-Bay area preclinical company focused on the ATP Binding Cassette A1 (ABCA1) transporter biology. Current therapy areas of interest include a) homozygous ApoE4-driven Alzheimer’s disease found in 20 percent of Alzheimer’s disease patients, b) atherosclerosis diseases including cardiovascular disease and stroke, and c) type 2 diabetes mellitus (T2DM). For more information, please visit www.arterytx.com.

For further information, please contact: Ramot at Tel Aviv University: Maya Kotler, maya.kotler(at)ramot.org Berkeley Lab: Suzanne Storar, ststorar(at)lbl.gov Artery: Johannes Johansson, johannes(at)arterytx.com
Contact Information
Johannes Johansson
Artery Therapeutics, Inc.
http://www.arterytx.com
+1 (415) 669-4821

Online Web 2.0 Version
You can read the online version of this press release here.